Mounjaro Science

Good overview on Mounjaro and Obesity

Lilly Press Release on Surmont-1 Results on Weight Loss

Once Weekly Treatment for Obesity Trial (Surmont-1)

Editorial in NEJM on Surmont-1 Study

Tirzepatide (Mounjaro) is an imbalanced and biased dual GIP and GLP-1 receptor agonist

The Science Behind How We Really Burn Calories – Scientific American

Mounjaro Mechanism of Action